Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934433 | 0.86 | GAA (0.61) | CTSLCTSBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11986720 | 0.84 | GAA (0.51) | SMN1; SMN2ALDH1A1LMNAHTTRAB9A | |
| SCHEMBL15187708 | 0.83 | RAB9A (0.57) | SMN1; SMN2ALDH1A1LMNARAB9AHPGD | |
| SCHEMBL16863760 | 0.83 | SMN1; SMN2 (0.56) | CTSLCTSBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL18672224 | 0.82 | GAA (0.63) | SMN1; SMN2ALDH1A1LMNAHTTHPGD | |
| SCHEMBL31213415 | 0.82 | SMN1; SMN2 (0.51) | CTSLCTSBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL933860 | 0.81 | MEN1 (0.69) | CTSLSMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL29420498 | 0.81 | MEN1 (0.49) | SMN1; SMN2ALDH1A1LMNAHTTRAB9A | |
| SCHEMBL3818727 | 0.81 | MAPT (0.56) | SMN1; SMN2ALDH1A1LMNAHTTRAB9A | |
| SCHEMBL29420482 | 0.80 | SMN1; SMN2 (0.54) | CTSLCTSBSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557248-B2 | Method of forming a carbon-heteroatom bond | RHODIA CHIMIE (FR) | 2009-07-07 | — | — | US | claimed |
| US-20070243999-A1 | Method of Forming a Carbon-Heteroatom Bond | RHODIA CHIMIE (FR) | 2007-10-18 | — | — | US | claimed |
| CN-118880357-A | Benzoxazine derivative and electrochemical synthesis method thereof | 齐齐哈尔医学院 | 2024-11-01 | — | — | CN | disclosed |
| CN-114195676-B | Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs | 广州药本君安医药科技股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114195676-A | Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs | 广州药本君安医药科技股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-9063126-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2344505-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011008312-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010036998-A2 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7557248-B2 | Method of forming a carbon-heteroatom bond | RHODIA CHIMIE (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20070243999-A1 | Method of Forming a Carbon-Heteroatom Bond | RHODIA CHIMIE (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CTSL 4137/4885CTSB 3455/4885SMN1; SMN2 3913/4885 |
| US-20180024144-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CTSL 4137/4885CTSB 3455/4885SMN1; SMN2 3913/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CTSL 4137/4885CTSB 3455/4885SMN1; SMN2 3913/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | CTSL 4137/4885CTSB 3455/4885SMN1; SMN2 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.